




CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop Disclosure Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date:

9/13/06

By:


Winsome A. St. Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Martin Dugas, et al.

SERIAL NO.: 10/576,093

PCT FILING DATE: NOVEMBER 4, 2004:

FOR: **METHOD FOR DISTINGUISHING
MLL-PTD-POSITIVE AML FROM OTHER
AML SUBTYPES**

)

) EXAMINER: Unassigned

) ART UNIT: Unassigned

) Confirmation No. N/A

) Docket No. 22339-US

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosure.
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.


Applicants wish to provide the USPTO with an electronic copy of WO 03/039433A2, which is in excess of 2,900 pages.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date: 9/12/06


Robert W. Mann
Reg. No. 48,555

Correspondence Address:
Roche Molecular Systems, Inc
1145 Atlantic Avenue
Alameda, CA 94501
Tele: (510) 814-2800
Fax: (510) 814-2973

LIST OF INFORMATION CITED BY APPLICANT
(Use several sheets if necessary)

Applicants: Martin Dugas, et al.

International Filing Date: November 4, 2004

Group: N/A

U.S. PATENT DOCUMENTS

* EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
1	5,210,015	05/11/93	Gelfand, et al	435	6	08/06/90
2	5,445,934	08/29/95	Fodor, et al	435	6	09/30/92
3	5,487,972	01/30/96	Gelfand, et al	435	6	01/05/93
4	5,700,637	12/23/97	E. Southern	435	6	04/19/94
5	5,744,305	04/28/98	Fodor, et al	435	6	06/06/95
6	5,804,375	09/08/98	Gelfand, et al	435	6	04/25/95
7	5,945,334	08/31/99	Besemer, et al	435	287.2	06/07/95
8	6,174,670 B1	01/16/01	Wittwer, et al	435	6	06/04/97
9	2003/0138793 A1	07/24/03	Su, et al	435	6	06/10/02

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
10	0 373 203 B1	08/31/94	EP			
11	0 619 321 B1	01/07/90	EP			
12	1 043 676 A1	10/11/00	EP			
13	EP/2004/012469 Search Reports	11/04/04	PCT			
14	WO 92/02638	02/20/92	PCT			
15	WO 03/039443 A2	05/15/03	PCT			
16	WO 2005/0431602	05/12/05	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

17	Alizadeh, A., et al., 1999, "The Lymphochip: A Specialized cDNA Microarray for the Genomic-scale Analysis of Gene Expression in Normal and Malignant Lymphocytes", Cold Springs Harbor Symposium on Quantitative Biology, Volume LXIV, Cold Springs Harbor Laboratory Press, pp 71-78
18	Brown, M., et al, 2000, "Knowledge-based analysis of microarray gene expression data by using support vector machines, PNAS, 97(1):262-267
19	Connor, S., et al, 2002, "Identification of an adaptor-associated kinase, AAK1., as a regulator of clathrin-mediated endocytosis", The Journal of Cell Biology, 156(5):921-929
20	Dugas, M., et al., 2001, "A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping", Leukemia, 15:1805-1810
21	Dugas, M., et al., 2002, "Impact of Integrating Clinical and Genetic Information", In Silico Biology, 2:383-391
22	Furey, T., et al., 2000, "Support vector machine classification and validation of cancer tissue samples using microarray expression data", Bioinformatics, 16(10):906-914
23	Golub, T., et al, 1999, "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", Science, 286:531-537

	24	Haferlach, T., et al., 2002, "Abstract: Gene Expression Profiling is Able to Reproduce Different Phenotypes in AML as Defined by the FAB Classification", <i>Blood</i> , 100, Abstract 731
	25	Harlow, E., et al, 1988, "Antibodies A Laboratory Manual", <i>Cold Spring Harbor Laboratory</i>
	26	Koehler, G., et al., 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", <i>Nature</i> , 256:495-497
	27	Kohlmann, A., et al., 2002, "Abstract: A Simplified and Partially Automated target Preparation Method for Gene Expression Profiling", <i>Blood</i> , 100, Abstract 4287
	28	Kohlmann, A., et al., 2003, "Molecular Characterization of Acute Leukemias by Use of Microarray Technology", <i>Genes, Chromosomes & Cancer</i> , 37:396-405
	29	Liu, G., et al., 2003, "NetAffx: Affymetrix probesets and annotations", <i>Nucleic Acids Research</i> , 31(1):82-86
	30	Neben, K., et al., 2002, "Acute Myeloid Leukemia with Normal Karyotype and Mutation of the FLT3 or MLL Gene Are Characterized by Specific Gene Expression Profiles", <i>Blood</i> , 100, Abstract 2172
	31	Sambrook, J., et al., 1989, "Molecular Cloning A Laboratory Manual Second Edition", <i>Cold Spring harbor Laboratory Press</i> ,
	32	Schnittger, S., et al., 2002, "Partial tandem duplications (PTD) of the MLL gene: A study of 1603 patients reveals high frequency in secondary acute myeloid leukemia and low association with trisomy 11", <i>Blood</i> , 98(11 part 1): 801a
	33	Schnittger, S., et al., 2002, "Acute Myeloid Leukemia (AML) with Partial tandem duplications of the MLL-Gene (MLL-PTD) Can Be Discriminated from MLL-Translocations based on specific gene expression profiles", <i>Blood</i> , 100, Abstract 1202
	34	Schoch, C., et al., 2001, "Abstract: Specific abnormalities on the genomic level result in a distinct gene expression pattern detected by oligonucleotide microarrays: An analysis of 25 patients with AML M2/t (8;21), AML M3/M3v/t (15;17), and AML M4eo/inv(16), <i>Blood</i> , 98: pp 92a – 93a
	35	Schoch, C., et al., 2002, "Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles", <i>PNAS</i> , 99(15):10008-10013
	36	Storey, J., et al., 2003, "Statistical significance for genomewide studies," <i>PNAS</i> , 100(16):9440-9445
EXAMINER		DATE CONSIDERED
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		